Published in Epilepsia on March 26, 2007
Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial. Epilepsia (2014) 2.60
Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology (2015) 1.84
Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology (2011) 1.04
The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research. Brief Funct Genomic Proteomic (2008) 1.01
Risk factors associated with DRESS syndrome produced by aromatic and non-aromatic antipiletic drugs. Eur J Clin Pharmacol (2011) 0.95
Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol (2014) 0.95
Clinical utility of eslicarbazepine: current evidence. Drug Des Devel Ther (2015) 0.87
Pharmacotherapy for Status Epilepticus. Drugs (2015) 0.87
Neurobehavioral effects of levetiracetam in brain tumor related epilepsy. Front Neurol (2013) 0.86
Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs (2009) 0.82
Antiepileptic drugs' tolerability and safety - a systematic review and meta-analysis of adverse effects in dogs. BMC Vet Res (2016) 0.82
Safety of lamotrigine in paediatrics: a systematic review. BMJ Open (2015) 0.82
International veterinary epilepsy task force consensus proposal: outcome of therapeutic interventions in canine and feline epilepsy. BMC Vet Res (2015) 0.81
Carbamazepine hypersensitivity: progress toward predicting the unpredictable. Epilepsy Curr (2011) 0.81
Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development. Pharmaceuticals (Basel) (2010) 0.80
Toxic epidermal necrolysis due to concomitant use of lamotrigine and valproic Acid. Indian J Dermatol (2013) 0.78
Absence of HLA-B*1502 and HLA-A*3101 alleles in 9 Korean patients with antiepileptic drug-induced skin rash: a preliminary study. Ann Lab Med (2014) 0.77
Treating epilepsy across its different stages. Ther Adv Neurol Disord (2010) 0.76
The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population. BMC Neurol (2013) 0.76
Relationship Between Acute Benzodiazepine Poisoning and Acute Pancreatitis Risk: A Population-Based Cohort Study. Medicine (Baltimore) (2015) 0.75
Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report. J Med Case Rep (2012) 0.75
Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy. Pharmaceuticals (Basel) (2010) 0.75
A case of syndrome of inappropriate scretion of anti-diuretic hormone associated with sodium valproate. Electrolyte Blood Press (2012) 0.75
Anticonvulsant potential of certain new (2E)-2-[1-Aryl-3-(1H-imidazol-1-yl)propylidene]-N-(aryl/H)hydrazinecarboxamides. ScientificWorldJournal (2014) 0.75
Valproic Acid-Induced Severe Acute Pancreatitis with Pseudocyst Formation: Report of a Case. Cureus (2015) 0.75
Anticonvulsant profiles of certain new 6-aryl-9-substituted-6,9-diazaspiro-[4.5]decane-8,10-diones and 1-aryl-4-substituted-1,4-diazaspiro[5.5]undecane-3,5-diones. Int J Mol Sci (2014) 0.75
Adult-onset temporal lobe epilepsy, cognitive decline, multi-antiepileptic drug hypersensitivity, and Hashimoto's encephalopathy: Two case studies. Epilepsy Behav Case Rep (2013) 0.75
Health-related quality of life in epilepsy patients receiving anti-epileptic drugs at National Referral Hospitals in Uganda: a cross-sectional study. Health Qual Life Outcomes (2014) 0.75
Hepatoprotective and antioxidant activity of N-acetyl cysteine in carbamazepine-administered rats. Indian J Pharmacol (2014) 0.75
Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature. Clin Mol Allergy (2017) 0.75
Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance. Drug Saf (2017) 0.75
ILAE official report: a practical clinical definition of epilepsy. Epilepsia (2014) 7.12
Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2009) 7.03
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol (2011) 3.93
ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2006) 3.69
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 2.88
Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia (2008) 2.74
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Antiepileptic drug therapy: does mechanism of action matter? Epilepsy Behav (2011) 2.20
International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia (2013) 1.82
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol (2003) 1.76
Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol (2009) 1.73
Postinfectious neurologic syndromes: a prospective cohort study. Neurology (2013) 1.73
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2013) 1.69
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60
Vigabatrin and epilepsy: lessons learned. Epilepsia (2007) 1.55
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology (2014) 1.45
Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia (2012) 1.45
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci (2010) 1.45
Sertraline-induced potentiation of the CYP3A4-dependent neurotoxicity of carbamazepine: an in vitro study. Epilepsia (2015) 1.40
Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia (2009) 1.38
Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: reply to Beyenburg et al., 2009. Epilepsia (2010) 1.37
Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res (2010) 1.35
The ketogenic diet: from molecular mechanisms to clinical effects. Epilepsy Res (2006) 1.30
Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia (2011) 1.27
Retracted Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. Mult Scler Int (2011) 1.26
Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res (2012) 1.24
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res (2006) 1.23
An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia (2007) 1.23
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol (2003) 1.20
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia (2011) 1.20
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res (2008) 1.20
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia (2007) 1.19
Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler (2011) 1.19
Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia (2002) 1.17
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia (2004) 1.16
Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol (2009) 1.10
Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J Neuroinflammation (2012) 1.08
EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia (2004) 1.07
Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci (2011) 1.07
Revisiting phenobarbital for epilepsy. BMJ (2004) 1.07
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. Epilepsia (2013) 1.07
Epilepsy after head injury. Curr Opin Neurol (2004) 1.06
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res (2004) 1.05
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia (2012) 1.04
Cell-cycle inhibition by Helicobacter pylori L-asparaginase. PLoS One (2010) 1.04
Transketolase and 2',3'-cyclic-nucleotide 3'-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients. Mol Cell Proteomics (2008) 1.02
Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res (2003) 1.01
Cerebrospinal fluid analysis in immunoglobulin G4-related hypertrophic pachymeningitis. J Rheumatol (2013) 1.01
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. Neurology (2012) 1.00
Lymphoid chemokines in chronic neuroinflammation. J Neuroimmunol (2008) 1.00
Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia (2010) 0.99
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. Arch Neurol (2007) 0.98
Immunological patterns identifying disease course and evolution in multiple sclerosis patients. J Neuroimmunol (2005) 0.97
New and forthcoming anti-epileptic drugs. Curr Opin Neurol (2011) 0.97
Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mult Scler (2013) 0.96
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Gender-based blood transcriptomes and interactomes in multiple sclerosis: involvement of SP1 dependent gene transcription. J Autoimmun (2011) 0.95
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia (2002) 0.95
Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. J Proteomics (2012) 0.95
Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia (2013) 0.94
Treatment of epilepsy in developing countries. BMJ (2007) 0.94
Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia (2014) 0.93
Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med (2010) 0.92
Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia (2014) 0.91
Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol (2005) 0.90
Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Res (2010) 0.90
Severe steroid-resistant post-infectious encephalomyelitis: general features and effects of IVIg. J Neurol (2007) 0.89
The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data. Epilepsy Res (2006) 0.88
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia (2006) 0.87
Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Epilepsy Res (2004) 0.87
Congenital adrenal hyperplasia and multiple sclerosis: is there an increased risk of multiple sclerosis in individuals with congenital adrenal hyperplasia? Arch Neurol (2004) 0.87
Novel medications for epilepsy. Drugs (2011) 0.86
Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers. Eur J Clin Pharmacol (2009) 0.86
Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.86
Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia. Neurol Sci (2008) 0.86
Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs (2009) 0.86
Differential diagnosis between acute disseminated encephalomyelitis and multiple sclerosis during the first episode. Arch Neurol (2008) 0.86
The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up study. Neurology (2004) 0.86
The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia (2014) 0.86
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol (2002) 0.86
Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet (2013) 0.85
Recurrent ADEM versus MS: differential diagnostic criteria. Neurol Res (2008) 0.85
Antibodies to cerebellar nerve fibres in two patients with paraneoplastic cerebellar ataxia. Anticancer Res (2005) 0.84
Revised diagnostic criteria for neuromyelitis optica--incorporation of NMO-IgG status. Nat Clin Pract Neurol (2007) 0.84
A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia (2011) 0.84
Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit (2003) 0.84
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia (2005) 0.84
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit (2006) 0.84
Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. Ther Drug Monit (2008) 0.84
Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res (2005) 0.83
Increased apparent oral clearance of valproic acid during intake of combined contraceptive steroids in women with epilepsy. Epilepsia (2006) 0.83
Dopaminergic receptor D5 mRNA expression is increased in circulating lymphocytes of Tourette syndrome patients. J Psychiatr Res (2008) 0.83
A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia (2011) 0.83
Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet (2005) 0.83
Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation (2014) 0.83
Commentary: Epilepsy is a Global Problem. Epilepsia (2014) 0.83
Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat (2008) 0.83
Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy. Epilepsia (2006) 0.83